CJC-1295 typical research dosing
Across the available literature, CJC-1295 is most commonly administered at 100–300 mcg per dose, 1 time(s) per day, via subcutaneous injection. CJC-1295 no-DAC is typically used at 100 mcg up to 3× daily; CJC-1295 with DAC is used once or twice weekly at 1–2 mg.
CJC-1295 unit-conversion table
The number of insulin-syringe units you draw depends on how much bacteriostatic water you used to reconstitute the vial. The table below shows units to draw on a U-100 syringe for a 2 mg CJC-1295 vial at common reconstitution volumes.
| Diluent (mL) | Concentration | 100 mcg | 200 mcg | 300 mcg |
|---|---|---|---|---|
| 1 mL | 2000 mcg/mL | 5.0 units | 10.0 units | 15.0 units |
| 2 mL | 1000 mcg/mL | 10.0 units | 20.0 units | 30.0 units |
| 3 mL | 667 mcg/mL | 15.0 units | 30.0 units | 45.0 units |
| 5 mL | 400 mcg/mL | 25.0 units | 50.0 units | 75.0 units |
CJC-1295 cycle length
Most reported CJC-1295 protocols run 8 weeks on, then 4 weeks off. Cycles are used in research to study washout, receptor sensitivity, and to re-baseline endogenous signaling before re-introducing the compound.
CJC-1295 half-life and timing
CJC-1295 has a half-life of approximately 8 hours. This influences dose frequency: shorter half-lives often require multiple doses per day to maintain steady-state levels, while longer half-lives can be dosed less frequently.